Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale. Read More
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2025 financial results and provide a business update.
Gilead Sciences (GILD) presents a strong value investing case with a low P/E ratio, high profitability, and solid cash flow, suggesting the stock may be undervalued.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market.
But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by Danish biotech giant Genmab A/S (NASDAQ: GMAB). The all-cash transaction, valued at approximately $8.0 billion, represents
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a spending bill, with crucial negotiations underway to avert what would be the 15th partial federal government shutdown since 1981. This looming
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engineering and math (STEM) education pathways in the San Francisco Bay Area and beyond. The funding, distributed through the Gilead Foundation, will build on the company’s ongoing work to cultivate a robust talent pipeline comprised of students from a broad spectrum of backgrounds and experiences. These donations represent an ongoing commitment to supporting organizations where Gilead colleagues live and work, including a $1 million grant to the Boys and Girls Clubs of America and $500,000 to the San Mateo Foster City Education Foundation to build STEM curriculum.
Gilead Sciences (GILD) shows strong technicals with a top rating of 9. It's forming a high-quality consolidation pattern, suggesting a potential breakout above $117.42.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Fayetteville, NC - September 18, 2025 - First in Families of North Carolina (FIFNC) Cumberland County will host the 2nd Annual Mister & Miss FIFNC Pageant on Saturday, October 18, 2025, at 2:00 p.m. The event will take place at Balm In Gilead Family Counseling Ministries, 3110 Doc Bennett Road, Fayetteville, NC 28306, and aims to celebrate the talents, confidence, and achievements of individuals living with disabilities.
